Erythropoietin: a multimodal neuroprotective agent

Nadiya Byts

Anna-Leena Sirén

Abstract

The cytokine erythropoetin (EPO)

The cytokine erythropoietin (EPO) is a 34 kD glycoprotein which was originally described to stimulate erythropoiesis. EPO supports the proliferation and differentiation of erythroid progenitor cells and is critical for their survival [1]. The main site of EPO production is fetal liver and adult kidney [1]. Mice deficient for EPO or EPO receptor (EPOR) genes die at embryonic day 13 (E13) because of severe anemia caused by deficiency in definitive erythropoiesis [2-4]. Over the last decade it has become clear that EPO acts as growth and survival factors for multiple tissues expressing the EPO receptor [1]. The number of described targets of EPO action continues to grow.

EPO Receptor (EPOR)

EPO acts by binding to its specific transmembrane receptor (EPOR). EPOR belongs to the single-chain cytokine type I receptor family [5]. These receptors are characterized by an extracellular N-terminal domain with conserved cysteines and a WSXWS-motif, a single hydrophobic transmembrane segment and a cytosolic domain with no intrinsic kinase activity [5]. Two transmembrane EPOR molecules form a homodimer that binds one EPO molecule leading to a conformational change and tight bonding of the two EPOR monomers which in turn activate two Janus family tyrosine kinase 2 (JAK2) molecules which associate with cytoplasmic domain of the EPOR. Once activated, JAK2 phosphorylates distal parts of receptors which subsequently serve as docking sites for downstream signaling molecules. Multiple signal transduction pathways are activated downstream of EPOR/JAK2 [1,5]. In neurons these include signal transducers and activators of transcription (Stat), phosphatidylinositol 3-kinase (PI3K)/Akt, Ras/extracellular signal regulated kinase (ERK1/2), nuclear factor-kappa-B (NF-κB), and calcium [6-8]. Best investigated from these are PI3K/Akt and Ras-MAPK pathways, both of which are important for the antiapoptotic and trophic effects of EPO [8-18]. NFκB pathway plays a role in antiapoptotic activity of EPO in neurons [7,19,20] as well as in EPO-mediated propagation of neural stem cells [21]. In addition EPO by activating phospholipase Cγ modulates intracellular calcium concentration, electrical activity and neurotransmitter release in PC12 cells [22-24] as well as in hippocampal neurons and brain slices [25,26]. The role of the Stat transcriptional factors in regard to EPO effects in the neural cells remains unclear; EPO induces phosphorylation of Stat5 in neurons [8,19,27], neural stem cells [21] and neuroblastoma cells [17,28]. Using primary hippocampal neurons from Stat5a/b knock-out mice we have recently shown that the presence of functional Stat5 is required for the trophic but not for the protective effect of EPO against glutamate-induced toxicity [9].

EPO signaling is terminated by activation of phosphatases which dephosphorylate JAK2. The ligand-receptor complex is then internalized and degraded by the proteasome [1,5]. In hematopoietic cell lines 60% of the internalized EPO is re-secreted [29].

The brain EPO/EPOR system

mRNA and protein of EPO and EPOR are detected in brain (hippocampus, internal capsule, cortex, midbrain), as well as in vitro in neurons, astrocytes, oligodendrocytes, microglia and cerebral endothelial cells [24,30-44] suggesting that this factor can function in the brain in a paracrine and/or autocrine manner. In the developing mouse brain expression of EPO and EPOR peaks during midgestation and decreases to adult levels in late gestation [43]. Brain specific ablation of EPOR leads to deficits in neural cell proliferation and neuronal survival in the embryonic brain and in post-stroke neurogenesis in the adult brain [45,46]. Expression of EPO and EPOR in the adult brain is stress-responsive and is regulated by oxygen supply: Both receptor and ligand expression is upregulated after hypoxia or ischemia [36,42,43,47-50]. Other stimuli such as hypoglycemia, insulin release, reactive oxygen species and insulin-like growth factor activate hypoxia-inducible factor and lead to increased expression of EPO [51,52]. Proinflammatory cytokines downregulate expression of EPO mRNA but increase that of EPOR in astrocytes [34]

Based on the loss of some of the tissue protective effects of EPO and its non-hematopoietic derivative, the carbamylated EPO (CEPO) in mice lacking the common β chain shared by the members of the IL-3 receptor family, Brines and Cerami have proposed that the cytoprotective effects of EPO and CEPO are mediated by a heteromeric receptor complex comprised of one EPOR subunit and a dimer of the common β chain [6,53]. Immunoreactivity of the common β chain has been detected in brain tissue with a pattern reminiscent to that of the classical EPOR [53]. Furthermore, the common β chain can be coimmunoprecipitated with EPOR antibodies from the P19 embryonal carcinoma cells [53], but the existence of the proposed heteromeric receptor structure in primary cells or tissues has yet to be directly proven. In a recent study no expression of the common β subunit was detected in neuronal PC-12 cells even if EPO rescued these cells from staurosporine-induced apoptosis [28]. Interestingly, the classical EPOR is required for EPO-stimulated neuronal differentiation and survival but not for neurogenesis induced by CEPO suggesting that differential receptor interactions mediate the effects of EPO and CEPO in brain cells [28,54].

Neuroprotection by EPO is independent of hematopoesis

The neuroprotective actions of EPO can be separated from its hematopoietic actions, a fact that is of value for therapeutic applications where the increase in red cell mass is not desired. EPO and EPO derivatives are directly neuroprotective in cell culture models (see below) and after direct application into the brain [36,55,56]. Moreover, CEPO and other EPO derivatives which do not bind to EPOR in myeloid cells and thus lack hematopoietic activity display potent tissue protective activities [57-59]. Expression of EPO and the classical EPOR in brain cells is induced by hypoxic-ischemic stress and contributes to ischemic tolerance [14,24,32,37,41,49,50,60-66] while neutralization of the brain endogenous EPO augments ischemic damage [56]. Brain-specific genetic ablation of the classical EPOR impairs post-stroke neurogenesis and neuronal survival [45,46] whereas transgenic brain specific overexpression of human EPO is associated with reductions in postischemic infarct volume, brain swelling and functional deficits in a transient stroke model [16].

Multimodal neuroprotective profile

EPO has been reported to induce a broad range of cellular responses in the brain directed to protect and repair tissue damage (Figure 1). EPO is neuroprotective in a variety of hypoxic, hypoglycemic, and excitotoxic in vitro models [7,8,10,14,17,18,20,21,42,45,50,57,67-72]. A fundamental mechanism of EPO-induced neuroprotection in cultured neurons is its ability to inhibit apoptosis reducing both DNA damage and cell membrane asymmetry [7,8,10,14,17,18,20,21,42,45,50,57,67-72]. Necrotic cell death (for example, after glutamate exposure) is also be attenuated by EPO [9,69,73]. Why astroglial cultures are protected by EPO from nitric oxide- and staurosporine-induced death but not from arsenic trioxide- or glutamate-induced toxicity is not fully understood [73,74].

Figure 1

Multimodal neuroprotective profile of erythropoietin (EPO). BBB - blood brain barrier; EC - endothelial cells.

Another tissue-protective mechanism of EPO is its ability to protect cells against oxidative damage [75,76]. EPO inhibits lipid peroxidation by increasing the activities of cytosolic antioxidant enzymes such as superoxide dismutase and glutathione peroxidase [77-79].

EPO attenuates inflammation by reducing reactive astrocytosis and microglia activation and by inhibiting immune cells recruitment into the injured area [47,58,59,70,80-85]. In cerebrovascular endothelial cell cultures EPO down-regulates TNF-α-induced gene expression of interleukin-6 (IL-6), IL-1beta, CXCR4, and IL-1alpha [86]. It also directly counteracts interferon-γ- and lipopolyssaccharide-induced cytotoxicity in oligodendrocytes, preserves white matter [87] and reduces TNF-α release and its effects in cultured Schwann cells [88].

EPO protects vascular integrity and stimulates angiogenesis [89-92]. It preserves blood-brain barrier integrity during injury by restoring expression of tight junction proteins [90,93,94], by reducing vascular inflammation [95] and reactive free radical expression [90,93,94,96]. In vasculogenesis EPO stimulates proliferation of endothelial precursor cells, production of matrix metalloproteinase-2, migration of endothelial cells into vascular sites and formation of capillary tubes [90-92,97,98]. EPO displays direct antiapoptotic activity in cerebral endothelial cells during oxidative stress and ischemic injury as well [91]. Stimulation of endothelial nitric oxide synthase (eNOS) activity has been shown to contribute to the improvements by EPO after experimental cerebral hemorrhage [99-101]. Interestingly, plasma and tissue levels of NO are markedly increased in transgenic rats overexpressing EPO [102] whereas the vascular protection by EPO is abolished in eNOS-deficient mice [103].

EPO promotes differentiation towards neurons in several neuroblastoma cell lines, in neural stem cell cultures derived from both embryonic and adult neuronal germinal zones, as well as in embryonic neural progenitor-cell cultures [21,45,46,54,89,104-108]. Neuronal differentiation of adult neural progenitor cell by EPO seem to require activation of the sonic hedgehog signaling and up-regulation of suppressor of cytokine signaling-2 (SOCS2) [54,105]. EPO increases proliferation of oligodendrocyte progenitors and promotes differentiation of oligodendrocytes in culture [33,34]. EPOR^-/-fetuses exhibit increased apoptosis in the brain and a reduction in the number of neural progenitor cells, as well as increased sensitivity to hypoxia prior to significant anaemia or heart defects in the embryo proper [42,45,46]. Moreover, adult mice that lack EPOR in the brain have significantly reduced neurogenesis in the subventricular zone and demonstrate impaired migration of precursors into infracted cortex [46]. Nevertheless, expression of EPO or EPOR on neural cells is not indispensable for brain development [42,45,46].

The reported neurotrophic effects of EPO include the ability to stimulate axonal regrowth, neurite formation, dendritic sprouting, electrical activity and modulate intracellular calcium and neurotransmitter synthesis and release [9,13,22,23,25,26,46,109-113]. A recent study demonstrated a calcium sensitive activation of cAMP response element binding protein (CREB) and induction of brain-derived neurotrophic factor (BDNF) gene expression by EPO in primary hippocampal neurons [25]. In rat hippocampal slices, EPO improved synaptic transmission during and following oxygen and glucose deprivation [13]. However, it has not been directly shown that EPO induces formation of new synapses.

Animal Studies

The preclinical data in support of the use of EPO in human brain disease have explosively increased since the first discovery of its neuroprotective action. In particular, the preclinical evidence in support for testing EPO in human acute ischemic stroke fulfills most of the STAIR criteria [114] such as testing by several laboratories using both temporary and permanent stroke models, post-treatment at several doses and exploration of therapeutic window, characterization of pharmacokinetic profile in respect to blood-brain-barrier penetration after peripheral administration, measurement of histological and functional outcome with prolonged survival.

Cerebral ischemia

The in vivo potential of EPO to protect neurons against ischemic neuronal damage was first provided by the Sasaki group. Their landmark finding was that application of recombinant human (rh)EPO directly into the cerebral ventricles of gerbils prevented ischemia-induced learning disabilities and protected hippocampal pyramidal CA1 neurons from lethal ischemia while neutralization of the endogenous brain EPO by infusions of soluble EPOR before a nonlethal mild ischemia induced neuronal death [56]. Since the circulating EPO, as a large, highly glycosylated negatively charged molecule, was thought not to cross the blood-brain-barrier [91,115,116], the early studies used direct intracerebroventricular route of administration of EPO to demonstrate its potent tissue protective activity in focal and global models of cerebral ischemia [36,55,56]. The first evidence for a neuroprotective effect of EPO by peripheral route of administration was provided by Brines et al. (2000) who demonstrated in a focal stroke model reduction of infarct volumes by intraperitoneally applied high dose rhEPO (5000 U/kg) up to 6 h after reperfusion. Immunohistochemical detection of biotinylated rhEPO 5 hours after its intraperitoneal injection at the therapeutically effective dose (5000 U/kg) further provided evidence that EPO can cross the blood-brain barrier [117]. Studies in several species including man have confirmed the ability for high dose EPO to cross the blood-brain barrier in therapeutic effective concentrations [118-122]. To date EPO and its derivatives have shown to reduce histological damage and improve functional outcome when given as intraperitoneal or even intranasal post-treatment after experimental stroke [57-59,70,85,89,123], global cerebral ischemia [124], neonatal stroke and hypoxia-ischemia [107,125-128]. For example, a comprehensive dosing study using post-treatment with EPO and CEPO starting at 6 h after an embolic middle cerebral artery occlusion in rats demonstrated reduction of functional deficits and infarct volume up to 28 days models of middle cerebral artery occlusion [59]. Induction of EPO and its intracellular signaling intermediates represents a significant component of tolerance induced by ischemic or hypoxic preconditioning [60-62,65]. Here activation of the antiapoptotic and anti-inflammatory signaling seems to play a major role in the EPO-induced neuroprotection [14,19,129].

Cerebral hemorrhage

Post-treatment with EPO starting at 2 h after induction of intracerebral hemorrhage (ICH) by intraparenchymal injections of collagenase or autologous blood dose-dependently reduced volume of hemorrhage, brain edema, perihematomal apoptosis and inflammation in a rat model [99]. Functional recovery was faster and more efficient in the EPO-treated group and was associated with reduction in hemispheric brain atrophy 5 weeks after the induction of ICH [99]. Cerebral vasospasm and ischemic brain damage after subarachnoid hemorrhage (SAH) by autologous blood injections into the cisterna magna in rabbits are reduced by EPO administered either by intraperitoneal injections of rhEPO or by delivery of adenoviral vectors encoding the human EPO into cisterna magna immediately after induction of SAH [130-133]. Mortality and functional deficits 3 days after induction of SAH were reduced in EPO treated rabbits [130-132]. In a rat model of SAH, the impaired autoregulatory response of cerebral blood flow to intravenous noradrenaline was restored by a single subcutaneous bolus of EPO [134].

Traumatic brain and spinal cord injury

Administration of EPO and EPO-analogs in experimental models of traumatic brain and spinal cord injury leads to morphological, functional and cognitive recovery that can be attributed to a multitude of cytoprotective mechanisms including inhibition of apoptosis, anti-inflammatory and anti-oxidant actions, restoration of blood-brain barrier integrity, stimulation of neurogenesis and angiogenesis [67,95,96,104,117,135-146]. Induction of EPO and its protective down stream signaling via Akt seems also to account for the protective effect of heat acclimation stress in a closed head injury model [147,148]. Brain edema after experimental brain injury can effectively be attenuated by post-treatment with EPO [95,138,140]. A reduction of cytotoxic and vasogenic edema may be anticipated based on the direct actions of EPO on glutamate release [112] and on the endothelial barrier function (see above). It is not clear to date which from the panoply of neurorestorative effects of EPO are responsible for the long-term prevention of trauma-induced brain atrophy, cognitive and neurobehavioral dysfunction [104,135-137,146]. In this context it is interesting to note that chronic peripheral administration of EPO has been reported to improve spatial memory function and cognitive functioning in the context of an aversion task also in healthy mice [119,149]. Improved hippocampal functioning after a single intravenous bolus of EPO was recently shown in a study using functional magnetic resonance imaging in healthy human volunteers [150].

Degeneration & neuroinflammation

EPO and its analogs offer protection also in models of neurodegenerative and neuroinflammatory disease. In experimental autoimmunencephalitis (EAE), an animal model for multiple sclerosis (MS), treatment with EPO and EPO analogs can improve functional recovery, reduce tissue damage, inflammatory responses and blood-brain barrier leakage [47,80-84,117]. Beneficial effects of EPO have also been reported in models of peripheral axonal nerve injury, injury-induced Wallerian degeneration and HIV-associated sensory neuropathy [88,151,152]. Here, the anti-cytokine, anti-apoptotic, anti-oxidative and trophic effects on both neurons and oligodendrocyte progenitor cells by EPO seem to play an important role in reducing inflammation and preserving myelination and neuronal function [35,47,80-84,86-88,151].

Chronic neurodegeneration might also be a target for EPO therapy as EPO and its analogs can counteract degenerative processes in experimental models of Parkinson disease and amyotrophic lateral sclerosis (ALS) by inducing anti-oxidant enzymes, inhibiting apoptosis and stimulating axonal regeneration [78,153-155]. EPO improved graft survival of embryonic ventral mesencephalic dopamine neurons when transplanted into the striatum of 6-hydroxy-dopamine lesioned rats [156]. However, not all degenerative diseases seem to respond to EPO therapy [157].

Translation to human brain disease

EPO and its receptor are abundantly expressed in the developing human brain decreasing to a weak constitutive expression in the adult [30,39,41,66,119,158]. Hypoxia rapidly induces expression of brain EPO as evidenced by the increased expression of EPO in cerebrospinal fluid (CSF) or postmortem brain tissue in humans with traumatic brain injury, SAH, stroke and hypoxia [31,41,66,121,159,160]. Expression of EPOR has also been detected on myelin sheath of radicular nerves and in the epineurial blood vessels of sural nerves in the human peripheral nervous system [161,162]. Measurements of endogenous levels of EPO in CSF of patients with neurodegenerative diseases has revealed EPO in CSF of patients with ALS to be lower than in controls whereas patients with Alzheimer disease (AD) or vascular dementia had EPO levels comparable to control persons [163,164]. Astrocytic EPOR immunoreactivity in postmortem hippocampus and temporal cortex from subjects with AD or chronic schizophrenia has been reported to be increased as compared to age-matched control brains [119,158]. In AD, however, no association of EPOR-positive astrocytes was found with summary measures of global cognition or AD pathology [158].

Millions of patients have already been receiving EPO as a highly efficacious and safe treatment for anemia [1]. Indeed, the first proof-of-concept study on use of EPO in human acute ischemic stroke has already demonstrated that treatment of stroke patients with intravenous high dose EPO is not only well tolerated but is associated with improvement in clinical outcome at 30 days [120]. Encouraging results with the use of EPO as a neuroprotective agent have been recently reported in clinical pilot studies after out-of-hospital cardiac arrest [165], ureamia-associated peripheral neuropathy [166], chronic schizophrenia [167] and MS [145]. A small pilot study to probe the safety and efficacy of EPO in SAH was recently preliminarily terminated with no conclusive results because of low recruitment rate [168]. To date a randomized multicenter double blinded placebo-controlled clinical trial in acute ischemic stroke is running (for details see http://www.epo-study.de) reflecting the beginning of exploration of EPO and its analogs for clinical neuroprotection in large phase II/III setting.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

NB drafted the manuscript and designed the Figure. ALS corrected and wrote the final manuscript. Both authors read and approved the final manuscript.

References

1. JelkmannWErythropoietin after a century of research: younger than everEur J Haematol200778183205[PubMed][Google Scholar]
2. LinCSLimSKD'AgatiVCostantiniFDifferential effects of an erythropoietin receptor gene disruption on primitive and definitive erythropoiesisGenes Dev199610154164[PubMed][Google Scholar]
3. WuHLeeSHGaoJLiuXIruela-ArispeMLInactivation of erythropoietin leads to defects in cardiac morphogenesisDevelopment199912635973605[PubMed][Google Scholar]
4. WuHLiuXJaenischRLodishHFGeneration of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptorCell1995835967[PubMed][Google Scholar]
5. YoussoufianHLongmoreGNeumannDYoshimuraALodishHFStructure, function, and activation of the erythropoietin receptorBlood19938122232236[PubMed][Google Scholar]
6. BrinesMCeramiAEmerging biological roles for erythropoietin in the nervous systemNat Rev Neurosci20056484494[PubMed][Google Scholar]
7. DigicayliogluMLiptonSAErythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascadesNature2001412641647[PubMed][Google Scholar]
8. SirénALFratelliMBrinesMGoemansCCasagrandeSLewczukPKeenanSGleiterCPasqualiCCapobiancoAMenniniTHeumannRCeramiAEhrenreichHGhezziPErythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stressProc Natl Acad Sci USA20019840444049[PubMed][Google Scholar]
9. BytsNSamoylenkoAFasshauerTIvanisevicMHennighausenLEhrenreichHSirénALEssential role for Stat5 in the neurotrophic but not in the neuroprotective effect of erythropoietinCell Death and Differentiation200815783792[PubMed][Google Scholar]
10. KilicUKilicESolizJBassettiCIGassmannMHermannDMErythropoietin protects from axotomy-induced degeneration of retinal ganglion cells by activating ERK-1/-2Faseb J200519249251[PubMed][Google Scholar]
11. DigicayliogluMGardenGTimberlakeSFletcherLLiptonSAAcute neuroprotective synergy of erythropoietin and insulin-like growth factor IProc Natl Acad Sci USA200410198559860[PubMed][Google Scholar]
12. ChongZZKangJQMaieseKErythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathwaysBr J Pharmacol200313811071118[PubMed][Google Scholar]
13. WeberAMaierRFHoffmannUGripsMHoppenzMAktasAGHeinemannUObladenMSchuchmannSErythropoietin improves synaptic transmission during and following ischemia in rat hippocampal slice culturesBrain Res2002958305311[PubMed][Google Scholar]
14. RuscherKFreyerDKarschMIsaevNMegowDSawitzkiBPrillerJDirnaglUMeiselAErythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro modelJ Neurosci2002221029110301[PubMed][Google Scholar]
15. ChongZZLinSHKangJQMaieseKErythropoietin prevents early and late neuronal demise through modulation of Akt1 and induction of caspase 1, 3, and 8J Neurosci Res200371659669[PubMed][Google Scholar]
16. KilicEKilicUSolizJBassettiCLGassmannMHermannDMBrain-derived erythropoietin protects from focal cerebral ischemia by dual activation of ERK-1/-2 and Akt pathwaysFaseb J20051920262028[PubMed][Google Scholar]
17. UmMLodishHFAntiapoptotic effects of erythropoietin in differentiated neuroblastoma SH-SY5Y cells require activation of both the STAT5 and AKT signaling pathwaysJ Biol Chem200628156485656[PubMed][Google Scholar]
18. WuYShangYSunSLiangHLiuRErythropoietin prevents PC12 cells from 1-methyl-4-phenylpyridinium ion-induced apoptosis via the Akt/GSK-3beta/caspase-3 mediated signaling pathwayApoptosis20071213651375[PubMed][Google Scholar]
19. LiuJNarasimhanPYuFChanPHNeuroprotection by Hypoxic Preconditioning Involves Oxidative Stress-Mediated Expression of Hypoxia-Inducible Factor and ErythropoietinStroke20053612641269[PubMed][Google Scholar]
20. ChongZZLiFMaieseKErythropoietin requires NF-kappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicityCurr Neurovasc Res20052387399[PubMed][Google Scholar]
21. ShingoTSorokanSTShimazakiTWeissSErythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cellsJ Neurosci20012197339743[PubMed][Google Scholar]
22. KawakamiMIwasakiSSatoKTakahashiMErythropoietin inhibits calcium-induced neurotransmitter release from clonal neuronal cellsBiochem Biophys Res Commun2000279293297[PubMed][Google Scholar]
23. KoshimuraKMurakamiYSohmiyaMTanakaJKatoYEffects of erythropoietin on neuronal activityJ Neurochem19997225652572[PubMed][Google Scholar]
24. MasudaSNagaoMTakahataKKonishiYGallyasFJrTabiraTSasakiRFunctional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cellsJ Biol Chem19932681120811216[PubMed][Google Scholar]
25. VivianiBBartesaghiSCorsiniEVillaPGhezziPGarauAGalliCLMarinovichMErythropoietin protects primary hippocampal neurons increasing the expression of brain-derived neurotrophic factorJ Neurochem200593412421[PubMed][Google Scholar]
26. YamamotoMKoshimuraKKawaguchiMSohmiyaMMurakamiYKatoYStimulating effect of erythropoietin on the release of dopamine and acetylcholine from the rat brain sliceNeurosci Lett2000292131133[PubMed][Google Scholar]
27. ZhangFWangSCaoGGaoYChenJSignal transducers and activators of transcription 5 contributes to erythropoietin-mediated neuroprotection against hippocampal neuronal death after transient global cerebral ischemiaNeurobiol Dis2007254553[PubMed][Google Scholar]
28. UmMGrossAWLodishHFA "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cellsCell Signal200719634645[PubMed][Google Scholar]
29. GrossAWLodishHFCellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP)J Biol Chem200628120242032[PubMed][Google Scholar]
30. JuulSEAndersonDKLiYChristensenRDErythropoietin and erythropoietin receptor in the developing human central nervous systemPediatr Res1998434049[PubMed][Google Scholar]
31. MartiHHGassmannMWengerRHKvietikovaIMorganti-KossmannMCKossmannTTrentzOBauerCDetection of erythropoietin in human liquor: intrinsic erythropoietin production in the brainKidney Int199751416418[PubMed][Google Scholar]
32. DigicayliogluMBichetSMartiHHWengerRHRivasLABauerCGassmannMLocalization of specific erythropoietin binding sites in defined areas of the mouse brainProc Natl Acad Sci USA19959237173720[PubMed][Google Scholar]
33. SugawaMSakuraiYIshikawa-IedaYSuzukiHAsouHEffects of erythropoietin on glial cell development; oligodendrocyte maturation and astrocyte proliferationNeurosci Res200244391403[PubMed][Google Scholar]
34. NagaiANakagawaEChoiHBHatoriKKobayashiSKimSUErythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in cultureJ Neuropathol Exp Neurol200160386392[PubMed][Google Scholar]
35. LiXGoniasSLCampanaWMSchwann cells express erythropoietin receptor and represent a major target for Epo in peripheral nerve injuryGlia200551254265[PubMed][Google Scholar]
36. BernaudinMMartiHHRousselSDivouxDNouvelotAMacKenzieETPetitEA potential role for erythropoietin in focal permanent cerebral ischemia in miceJ Cereb Blood Flow Metab199919643651[PubMed][Google Scholar]
37. MasudaSOkanoMYamagishiKNagaoMUedaMSasakiRA novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytesJ Biol Chem19942691948819493[PubMed][Google Scholar]
38. ChinKYuXBeleslin-CokicBLiuCShenKMohrenweiserHWNoguchiCTProduction and processing of erythropoietin receptor transcripts in brainBrain Res Mol Brain Res2000812942[PubMed][Google Scholar]
39. DameCBartmannPWolberEFahnenstichHHofmannDFandreyJErythropoietin gene expression in different areas of the developing human central nervous systemBrain Res Dev Brain Res20001256974[PubMed][Google Scholar]
40. KnabeWKnerlichFWashausenSKietzmannTSirénALBrunnettGKuhnHJEhrenreichHExpression patterns of erythropoietin and its receptor in the developing midbrainAnat Embryol (Berl)2004207503512[PubMed][Google Scholar]
41. SirénALKnerlichFPoserWGleiterCHBrückWEhrenreichHErythropoietin and erythropoietin receptor in human ischemic/hypoxic brainActa Neuropathol2001101271276[PubMed][Google Scholar]
42. YuXShackaJJEellsJBSuarez-QuianCPrzygodzkiRMBeleslin-CokicBLinCSNikodemVMHempsteadBFlandersKCCostantiniFNoguchiCTErythropoietin receptor signalling is required for normal brain developmentDevelopment2002129505516[PubMed][Google Scholar]
43. LiuZYChinKNoguchiCTTissue specific expression of human erythropoietin receptor in transgenic miceDev Biol1994166159169[PubMed][Google Scholar]
44. YamajiROkadaTMoriyaMNaitoMTsuruoTMiyatakeKNakanoYBrain capillary endothelial cells express two forms of erythropoietin receptor mRNAEur J Biochem1996239494500[PubMed][Google Scholar]
45. ChenZYAsavaritikraiPPrchalJTNoguchiCTEndogenous erythropoietin signaling is required for normal neural progenitor cell proliferationJ Biol Chem20072822587525883[PubMed][Google Scholar]
46. TsaiPTOhabJJKerteszNGroszerMMatterCGaoJLiuXWuHCarmichaelSTA critical role of erythropoietin receptor in neurogenesis and post-stroke recoveryJ Neurosci20062612691274[PubMed][Google Scholar]
47. DiemRSattlerMBMerklerDDemmerIMaierKStadelmannCEhrenreichHBahrMCombined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosisBrain2005128375385[PubMed][Google Scholar]
48. BernaudinMBellailAMartiHHYvonAVivienDDuchatelleIMackenzieETPetitENeurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brainGlia200030271278[PubMed][Google Scholar]
49. FandreyJOxygen-dependent and tissue-specific regulation of erythropoietin gene expressionAm J Physiol Regul Integr Comp Physiol2004286R977988[PubMed][Google Scholar]
50. LewczukPHasselblattMKamrowski-KruckHHeyerAUnzickerCSirénALEhrenreichHSurvival of hippocampal neurons in culture upon hypoxia: effect of erythropoietinNeuroreport20001134853488[PubMed][Google Scholar]
51. ChandelNSMaltepeEGoldwasserEMathieuCESimonMCSchumackerPTMitochondrial reactive oxygen species trigger hypoxia-induced transcriptionProc Natl Acad Sci USA1998951171511720[PubMed][Google Scholar]
52. MasudaSChikumaMSasakiRInsulin-like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytesBrain Res19977466370[PubMed][Google Scholar]
53. BrinesMGrassoGFiordalisoFSfacteriaAGhezziPFratelliMLatiniRXieQWSmartJSu-RickCJPobreEDiazDGomezDHandCColemanTCeramiAErythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptorProc Natl Acad Sci USA20041011490714912[PubMed][Google Scholar]
54. WangLZhangZGGreggSRZhangRLJiaoZLeTourneauYLiuXFengYGerwienJTorupLLeistMNoguchiCTChenZYChoppMThe Sonic hedgehog pathway mediates carbamylated erythropoietin-enhanced proliferation and differentiation of adult neural progenitor cellsJ Biol Chem20072823246232470[PubMed][Google Scholar]
55. SadamotoYIgaseKSakanakaMSatoKOtsukaHSakakiSMasudaSSasakiRErythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral arteryBiochem Biophys Res Commun19982532632[PubMed][Google Scholar]
56. SakanakaMWenTCMatsudaSMasudaSMorishitaENagaoMSasakiRIn vivo evidence that erythropoietin protects neurons from ischemic damageProc Natl Acad Sci USA19989546354640[PubMed][Google Scholar]
57. LeistMGhezziPGrassoGBianchiRVillaPFratelliMSavinoCBianchiMNielsenJGerwienJKallunkiPLarsenAKHelboeLChristensenSPedersenLONielsenMTorupLSagerTSfacteriaAErbayraktarSErbayraktarZGokmenNYilmazOCerami-HandCXieQWColemanTCeramiABrinesMDerivatives of erythropoietin that are tissue protective but not erythropoieticScience2004305239242[PubMed][Google Scholar]
58. VillaPvan BeekJLarsenAKGerwienJChristensenSCeramiABrinesMLeistMGhezziPTorupLReduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivativesJ Cereb Blood Flow Metab200727552563[PubMed][Google Scholar]
59. WangYZhangZGRhodesKRenziMZhangRLKapkeALuMPoolCHeavnerGChoppMPost-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemiaBr J Pharmacol200715113771384[PubMed][Google Scholar]
60. BergeronMGiddayJMYuAYSemenzaGLFerrieroDMSharpFRRole of hypoxia-inducible factor-1 in hypoxia-induced ischemic tolerance in neonatal rat brainAnn Neurol200048285296[PubMed][Google Scholar]
61. BernaudinMNedelecASDivouxDMacKenzieETPetitESchumann-BardPNormobaric hypoxia induces tolerance to focal permanent cerebral ischemia in association with an increased expression of hypoxia-inducible factor-1 and its target genes, erythropoietin and VEGF, in the adult mouse brainJ Cereb Blood Flow Metab200222393403[PubMed][Google Scholar]
62. DirnaglUSimonRPHallenbeckJMIschemic tolerance and endogenous neuroprotectionTrends Neurosci200326248254[PubMed][Google Scholar]
63. MartiHHErythropoietin and the hypoxic brainJ Exp Biol200420732333242[PubMed][Google Scholar]
64. MartiHHWengerRHRivasLAStraumannUDigicayliogluMHennVYonekawaYBauerCGassmannMErythropoietin gene expression in human, monkey and murine brainEur J Neurosci19968666676[PubMed][Google Scholar]
65. PrassKScharffARuscherKLowlDMuselmannCVictorovIKapinyaKDirnaglUMeiselAHypoxia-induced stroke tolerance in the mouse is mediated by erythropoietinStroke20033419811986[PubMed][Google Scholar]
66. SairanenTKarjalainen-LindsbergMLPaetauAIjasPLindsbergPJApoptosis dominant in the periinfarct area of human ischaemic stroke--a possible target of antiapoptotic treatmentsBrain2006129189199[PubMed][Google Scholar]
67. CelikMGokmenNErbayraktarSAkhisarogluMKonakcSUlukusCGencSGencKSagirogluECeramiABrinesMErythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injuryProc Natl Acad Sci USA20029922582263[PubMed][Google Scholar]
68. EhrenreichHHasselblattMKnerlichFvon AhsenNJacobSSperlingSWoldtHVehmeyerKNaveKASirénALA hematopoietic growth factor, thrombopoietin, has a proapoptotic role in the brainProc Natl Acad Sci USA2005102862867[PubMed][Google Scholar]
69. MorishitaEMasudaSNagaoMYasudaYSasakiRErythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal deathNeuroscience199776105116[PubMed][Google Scholar]
70. VillaPBiginiPMenniniTAgnelloDLaragioneTCagnottoAVivianiBMarinovichMCeramiAColemanTRBrinesMGhezziPErythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosisJ Exp Med2003198971975[PubMed][Google Scholar]
71. WenTCSadamotoYTanakaJZhuPXNakataKMaYJHataRSakanakaMErythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating Bcl-xL expressionJ Neurosci Res200267795803[PubMed][Google Scholar]
72. ZamanKRyuHHallDO'DonovanKLinKIMillerMPMarquisJCBarabanJMSemenzaGLRatanRRProtection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21(waf1/cip1), and erythropoietinJ Neurosci19991998219830[PubMed][Google Scholar]
73. SinorADGreenbergDAErythropoietin protects cultured cortical neurons, but not astroglia, from hypoxia and AMPA toxicityNeurosci Lett2000290213215[PubMed][Google Scholar]
74. DiazZAssarafMIMillerWHJrSchipperHMAstroglial cytoprotection by erythropoietin pre-conditioning: implications for ischemic and degenerative CNS disordersJ Neurochem200593392402[PubMed][Google Scholar]
75. WuYShangYSunSLiuRAntioxidant effect of erythropoietin on 1-methyl-4-phenylpyridinium-induced neurotoxicity in PC12 cellsEur J Pharmacol20075644756[PubMed][Google Scholar]
76. SolarogluISolarogluAKaptanogluEDedeSHaberalABeskonakliEKilincKErythropoietin prevents ischemia-reperfusion from inducing oxidative damage in fetal rat brainChilds Nerv Syst2003191922[PubMed][Google Scholar]
77. ChattopadhyayAChoudhuryTDBandyopadhyayDDattaAGProtective effect of erythropoietin on the oxidative damage of erythrocyte membrane by hydroxyl radicalBiochem Pharmacol200059419425[PubMed][Google Scholar]
78. GencSAkhisarogluMKuralayFGencKErythropoietin restores glutathione peroxidase activity in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced neurotoxicity in C57BL mice and stimulates murine astroglial glutathione peroxidase production in vitroNeurosci Lett20023217376[PubMed][Google Scholar]
79. KumralAGonencSAcikgozOSonmezAGencKYilmazOGokmenNDumanNOzkanHErythropoietin increases glutathione peroxidase enzyme activity and decreases lipid peroxidation levels in hypoxic-ischemic brain injury in neonatal ratsBiol Neonate2005871518[PubMed][Google Scholar]
80. AgnelloDBiginiPVillaPMenniniTCeramiABrinesMLGhezziPErythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitisBrain Res2002952128134[PubMed][Google Scholar]
81. LiWMaedaYYuanRRElkabesSCookSDowlingPBeneficial effect of erythropoietin on experimental allergic encephalomyelitisAnn Neurol200456767777[PubMed][Google Scholar]
82. SättlerMBMerklerDMaierKStadelmannCEhrenreichHBahrMDiemRNeuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosisCell Death Differ200411Suppl 2S181192[PubMed][Google Scholar]
83. ZhangJLiYCuiYChenJLuMEliasSBChoppMErythropoietin treatment improves neurological functional recovery in EAE miceBrain Res200510343439[PubMed][Google Scholar]
84. SavinoCPedottiRBaggiFUbialiFGalloBNavaSBiginiPBarberaSFumagalliEMenniniTVezzaniARizziMColemanTCeramiABrinesMGhezziPBianchiRDelayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitisJ Neuroimmunol20061722737[PubMed][Google Scholar]
85. YuYPXuQQZhangQZhangWPZhangLHWeiEQIntranasal recombinant human erythropoietin protects rats against focal cerebral ischemiaNeurosci Lett2005387510[PubMed][Google Scholar]
86. AvasaralaJRKonduruSSRecombinant Erythropoietin Down-Regulates IL-6 and CXCR4 Genes in TNF-alpha-Treated Primary Cultures of Human Microvascular Endothelial Cells: Implications for Multiple SclerosisJ Mol Neurosci200525183190[PubMed][Google Scholar]
87. GencKGencSBaskinHSeminIErythropoietin decreases cytotoxicity and nitric oxide formation induced by inflammatory stimuli in rat oligodendrocytesPhysiol Res2006553338[PubMed][Google Scholar]
88. CampanaWMLiXShubayevVIAngertMCaiKMyersRRErythropoietin reduces Schwann cell TNF-alpha, Wallerian degeneration and pain-related behaviors after peripheral nerve injuryEur J Neurosci200623617626[PubMed][Google Scholar]
89. WangLZhangZWangYZhangRChoppMTreatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in ratsStroke20043517321737[PubMed][Google Scholar]
90. RibattiDVaccaARoccaroAMCrivellatoEPrestaMErythropoietin as an angiogenic factorEur J Clin Invest200333891896[PubMed][Google Scholar]
91. MartiHHBernaudinMPetitEBauerCNeuroprotection and Angiogenesis: Dual Role of Erythropoietin in Brain IschemiaNews Physiol Sci200015225229[PubMed][Google Scholar]
92. JaquetKKrauseKTawakol-KhodaiMGeidelSKuckKHErythropoietin and VEGF exhibit equal angiogenic potentialMicrovasc Res200264326333[PubMed][Google Scholar]
93. Martinez-EstradaOMRodriguez-MillanEGonzalez-De VicenteEReinaMVilaroSFabreMErythropoietin protects the in vitro blood-brain barrier against VEGF-induced permeabilityEur J Neurosci20031825382544[PubMed][Google Scholar]
94. LiYLuZYOgleMWeiLErythropoietin prevents blood brain barrier damage induced by focal cerebral ischemia in miceNeurochem Res20073221322141[PubMed][Google Scholar]
95. ChenGShiJXHangCHXieWLiuJLiuXInhibitory effect on cerebral inflammatory agents that accompany traumatic brain injury in a rat model: a potential neuroprotective mechanism of recombinant human erythropoietin (rhEPO)Neurosci Lett2007425177182[PubMed][Google Scholar]
96. OzturkEDemirbilekSKadir ButASaricicekVGulecMAkyolOOzcan ErsoyMAntioxidant properties of propofol and erythropoietin after closed head injury in ratsProg Neuropsychopharmacol Biol Psychiatry200529922927[PubMed][Google Scholar]
97. Muller-EhmsenJSchmidtAKrausgrillBSchwingerRHBlochWRole of erythropoietin for angiogenesis and vasculogenesis: from embryonic development through adulthoodAm J Physiol Heart Circ Physiol2006290H331340[PubMed][Google Scholar]
98. WangLZhangZGZhangRLGreggSRHozeska-SolgotALeTourneauYWangYChoppMMatrix metalloproteinase 2 (MMP2) and MMP9 secreted by erythropoietin-activated endothelial cells promote neural progenitor cell migrationJ Neurosci20062659966003[PubMed][Google Scholar]
99. LeeSTChuKSinnDIJungKHKimEHKimSJKimJMKoSYKimMRohJKErythropoietin reduces perihematomal inflammation and cell death with eNOS and STAT3 activations in experimental intracerebral hemorrhageJ Neurochem20069617281739[PubMed][Google Scholar]
100. Beleslin-CokicBBCokicVPYuXWekslerBBSchechterANNoguchiCTErythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cellsBlood200410420732080[PubMed][Google Scholar]
101. SanthanamAVSmithLANathKAKatusicZSIn vivo stimulatory effect of erythropoietin on endothelial nitric oxide synthase in cerebral arteriesAm J Physiol Heart Circ Physiol2006291H781786[PubMed][Google Scholar]
102. RuschitzkaFTWengerRHStallmachTQuaschningTde WitCWagnerKLabuggerRKelmMNollGRulickeTShawSLindbergRLRodenwaldtBLutzHBauerCLuscherTFGassmannMNitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietinProc Natl Acad Sci USA2000971160911613[PubMed][Google Scholar]
103. d'UscioLVSmithLASanthanamAVRichardsonDNathKAKatusicZSEssential role of endothelial nitric oxide synthase in vascular effects of erythropoietinHypertension20074911421148[PubMed][Google Scholar]
104. LuDMahmoodAQuCGoussevASchallertTChoppMErythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injuryJ Neurotrauma20052210111017[PubMed][Google Scholar]
105. WangLZhangZZhangRHafnerMSWongHKJiaoZChoppMErythropoietin up-regulates SOCS2 in neuronal progenitor cells derived from SVZ of adult ratNeuroreport20041512251229[PubMed][Google Scholar]
106. StuderLCseteMLeeSHKabbaniNWalikonisJWoldBMcKayREnhanced proliferation, survival, and dopaminergic differentiation of CNS precursors in lowered oxygenJ Neurosci20002073777383[PubMed][Google Scholar]
107. GonzalezFFMcQuillenPMuDChangYWendlandMVexlerZFerrieroDMErythropoietin enhances long-term neuroprotection and neurogenesis in neonatal strokeDev Neurosci200729321330[PubMed][Google Scholar]
108. LingZDPotterEDLiptonJWCarveyPMDifferentiation of mesencephalic progenitor cells into dopaminergic neurons by cytokinesExp Neurol1998149411423[PubMed][Google Scholar]
109. KonishiYChuiDHHiroseHKunishitaTTabiraTTrophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivoBrain Res19936092935[PubMed][Google Scholar]
110. TabiraTKonishiYGallyasFJrNeurotrophic effect of hematopoietic cytokines on cholinergic and other neurons in vitroInt J Dev Neurosci199513241252[PubMed][Google Scholar]
111. CampanaWMMisasiRO'BrienJSIdentification of a neurotrophic sequence in erythropoietinInt J Mol Med19981235241[PubMed][Google Scholar]
112. KawakamiMSekiguchiMSatoKKozakiSTakahashiMErythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemiaJ Biol Chem20012763946939475[PubMed][Google Scholar]
113. LiptonSAErythropoietin for neurologic protection and diabetic neuropathyN Engl J Med200435025162517[PubMed][Google Scholar]
114. Recommendations for standards regarding preclinical neuroprotective and restorative drug developmentStroke19993027522758[PubMed][Google Scholar]
115. CeramiABeyond erythropoiesis: novel applications for recombinant human erythropoietinSemin Hematol2001383339[PubMed][Google Scholar]
116. SasakiRMasudaSNagaoMErythropoietin: multiple physiological functions and regulation of biosynthesisBiosci Biotechnol Biochem20006417751793[PubMed][Google Scholar]
117. BrinesMLGhezziPKeenanSAgnelloDde LanerolleNCCeramiCItriLMCeramiAErythropoietin crosses the blood-brain barrier to protect against experimental brain injuryProc Natl Acad Sci USA2000971052610531[PubMed][Google Scholar]
118. BanksWAJumbeNLFarrellCLNiehoffMLHeatheringtonACPassage of erythropoietic agents across the blood-brain barrier: a comparison of human and murine erythropoietin and the analog darbepoetin alfaEur J Pharmacol200450593101[PubMed][Google Scholar]
119. EhrenreichHDegnerDMellerJBrinesMBeheMHasselblattMWoldtHFalkaiPKnerlichFJacobSvon AhsenNMaierWBrückWRutherECeramiABeckerWSirénALErythropoietin: a candidate compound for neuroprotection in schizophreniaMol Psychiatry200494254[PubMed][Google Scholar]
120. EhrenreichHHasselblattMDembowskiCCepekLLewczukPStiefelMRustenbeckHHBreiterNJacobSKnerlichFBohnMPoserWRutherEKochenMGefellerOGleiterCWesselTCDe RyckMItriLPrangeHCeramiABrinesMSirénALErythropoietin therapy for acute stroke is both safe and beneficialMol Med20028495505[PubMed][Google Scholar]
121. JuulSEStallingsSAChristensenRDErythropoietin in the cerebrospinal fluid of neonates who sustained CNS injuryPediatr Res199946543547[PubMed][Google Scholar]
122. StatlerPAMcPhersonRJBauerLAKellertBAJuulSEPharmacokinetics of high-dose recombinant erythropoietin in plasma and brain of neonatal ratsPediatr Res200761671675[PubMed][Google Scholar]
123. BelayevLKhoutorovaLZhaoWVigdorchikABelayevABustoRMagalEGinsbergMDNeuroprotective effect of darbepoetin alfa, a novel recombinant erythropoietic protein, in focal cerebral ischemia in ratsStroke20053610711076[PubMed][Google Scholar]
124. CalapaiGMarcianoMCCoricaFAllegraAParisiAFrisinaNCaputiAPBuemiMErythropoietin protects against brain ischemic injury by inhibition of nitric oxide formationEur J Pharmacol2000401349356[PubMed][Google Scholar]
125. SpandouEPapadopoulouZSoubasiVKarkavelasGSimeonidouCPazaitiAGuiba-TziampiriOErythropoietin prevents long-term sensorimotor deficits and brain injury following neonatal hypoxia-ischemia in ratsBrain Res200510452230[PubMed][Google Scholar]
126. ChangYSMuDWendlandMSheldonRAVexlerZSMcQuillenPSFerrieroDMErythropoietin Improves Functional and Histological Outcome in Neonatal StrokePediatr Res200558106111[PubMed][Google Scholar]
127. KumralAUysalNTugyanKSonmezAYilmazOGokmenNKirayMGencSDumanNKorogluTFOzkanHGencKErythropoietin improves long-term spatial memory deficits and brain injury following neonatal hypoxia-ischemia in ratsBehav Brain Res20041537786[PubMed][Google Scholar]
128. AydinAGencKAkhisarogluMYorukogluKGokmenNGonulluEErythropoietin exerts neuroprotective effect in neonatal rat model of hypoxic-ischemic brain injuryBrain Dev200325494498[PubMed][Google Scholar]
129. MalhotraSSavitzSIOcavaLRosenbaumDMIschemic preconditioning is mediated by erythropoietin through PI-3 kinase signaling in an animal model of transient ischemic attackJ Neurosci Res2006831927[PubMed][Google Scholar]
130. AlafaciCSalpietroFGrassoGSfacteriaAPassalacquaMMorabitoATripodoECalapaiGBuemiMTomaselloFEffect of recombinant human erythropoietin on cerebral ischemia following experimental subarachnoid hemorrhageEur J Pharmacol2000406219225[PubMed][Google Scholar]
131. BuemiMGrassoGCoricaFCalapaiGSalpietroFMCasuscelliTSfacteriaAAloisiCAlafaciCSturialeAFrisinaNTomaselloFIn vivo evidence that erythropoietin has a neuroprotective effect during subarachnoid hemorrhageEur J Pharmacol20003923134[PubMed][Google Scholar]
132. GrassoGBuemiMAlafaciCSfacteriaAPassalacquaMSturialeACalapaiGDe VicoGPiedimonteGSalpietroFMTomaselloFBeneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhageProc Natl Acad Sci USA20029956275631[PubMed][Google Scholar]
133. SanthanamAVSmithLAAkiyamaMRosalesAGBaileyKRKatusicZSRole of endothelial NO synthase phosphorylation in cerebrovascular protective effect of recombinant erythropoietin during subarachnoid hemorrhage-induced cerebral vasospasmStroke20053627312737[PubMed][Google Scholar]
134. SpringborgJBMaXRochatPKnudsenGMAmtorpOPaulsonOBJuhlerMOlsenNVA single subcutaneous bolus of erythropoietin normalizes cerebral blood flow autoregulation after subarachnoid haemorrhage in ratsBr J Pharmacol2002135823829[PubMed][Google Scholar]
135. SirénALRadyushkinKBoretiusSKammerDRiechersCCNattOSarginDWatanabeTSperlingSMichaelisTPriceJMeyerBFrahmJEhrenreichHGlobal brain atrophy after unilateral parietal lesion and its prevention by erythropoietinBrain2006129480489[PubMed][Google Scholar]
136. XiongYMahmoodALuDQuCGoussevASchallertTChoppMRole of gender in outcome after traumatic brain injury and therapeutic effect of erythropoietin in miceBrain Res20071185301312[PubMed][Google Scholar]
137. MahmoodALuDQuCGoussevAZhangZGLuCChoppMTreatment of traumatic brain injury in rats with erythropoietin and carbamylated erythropoietinJ Neurosurg2007107392397[PubMed][Google Scholar]
138. GrassoGSfacteriaAMeliFFodaleVBuemiMIacopinoDGNeuroprotection by erythropoietin administration after experimental traumatic brain injuryBrain Res2007118299105[PubMed][Google Scholar]
139. LiaoZBZhiXGShiQHHeZHRecombinant human erythropoietin administration protects cortical neurons from traumatic brain injury in ratsEur J Neurol200815140149[PubMed][Google Scholar]
140. VerdonckOLahrechHFranconyGCarleOFarionRLooijY Van deRemyCSegebarthCPayenJFErythropoietin protects from post-traumatic edema in the rat brainJ Cereb Blood Flow Metab20072713691376[PubMed][Google Scholar]
141. MalaHRodriguez CastroMDall JorgensenKMogensenJEffects of erythropoietin on posttraumatic place learning in fimbria-fornix transected rats after a 30-day postoperative pauseJ Neurotrauma20072416471657[PubMed][Google Scholar]
142. CherianLGoodmanJCRobertsonCNeuroprotection with erythropoietin administration following controlled cortical impact injury in ratsJ Pharmacol Exp Ther2007322789794[PubMed][Google Scholar]
143. GorioAGokmenNErbayraktarSYilmazOMadaschiLCichettiCDi GiulioAMVardarECeramiABrinesMRecombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord traumaProc Natl Acad Sci USA20029994509455[PubMed][Google Scholar]
144. GrassoGSfacteriaAErbayraktarSPassalacquaMMeliFGokmenNYilmazOLa TorreDBuemiMIacopinoDGColemanTCeramiABrinesMTomaselloFAmelioration of spinal cord compressive injury by pharmacological preconditioning with erythropoietin and a nonerythropoietic erythropoietin derivativeJ Neurosurg Spine20064310318[PubMed][Google Scholar]
145. EhrenreichHFischerBNorraCSchellenbergerFStenderNStiefelMSirénALPaulusWNaveKAGoldRBartelsCExploring recombinant human erythropoietin in chronic progressive multiple sclerosisBrain200713025772588[PubMed][Google Scholar]
146. YatsivIGrigoriadisNSimeonidouCStahelPFSchmidtOIAlexandrovitchAGTsenterJShohamiEErythropoietin is neuroprotective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injuryFaseb J20051917011703[PubMed][Google Scholar]
147. SheinNAHorowitzMAlexandrovichAGTsenterJShohamiEHeat acclimation increases hypoxia-inducible factor 1alpha and erythropoietin receptor expression: implication for neuroprotection after closed head injury in miceJ Cereb Blood Flow Metab20052514561465[PubMed][Google Scholar]
148. SheinNATsenterJAlexandrovichAGHorowitzMShohamiEAkt phosphorylation is required for heat acclimation-induced neuroprotectionJ Neurochem200710315231529[PubMed][Google Scholar]
149. HengemihleJMAbugoORifkindJSpanglerEDanonDIngramDKChronic treatment with human recombinant erythropoietin increases hematocrit and improves water maze performance in micePhysiol Behav199659153156[PubMed][Google Scholar]
150. MiskowiakKO'SullivanUHarmerCJErythropoietin enhances hippocampal response during memory retrieval in humansJ Neurosci20072727882792[PubMed][Google Scholar]
151. KeswaniSCBuldanliogluUFischerAReedNPolleyMLiangHZhouCJackCLeitzGJHokeAA novel endogenous erythropoietin mediated pathway prevents axonal degenerationAnn Neurol200456815826[PubMed][Google Scholar]
152. KeswaniSCLeitzGJHokeAErythropoietin is neuroprotective in models of HIV sensory neuropathyNeurosci Lett2004371102105[PubMed][Google Scholar]
153. GencSKuralayFGencKAkhisarogluMFadilogluSYorukogluKFadilogluMGureAErythropoietin exerts neuroprotection in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57/BL mice via increasing nitric oxide productionNeurosci Lett2001298139141[PubMed][Google Scholar]
154. GrunfeldJFBarhumYBlondheimNRabeyJMMelamedEOffenDErythropoietin delays disease onset in an amyotrophic lateral sclerosis modelExp Neurol2007204260263[PubMed][Google Scholar]
155. MenniniTDe PaolaMBiginiPMastrottoCFumagalliEBarberaSMengozziMVivianiBCorsiniEMarinovichMTorupLVan BeekJLeistMBrinesMCeramiAGhezziPNonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivoMol Med200612153160[PubMed][Google Scholar]
156. KanaanNMCollierTJMarchioniniDMMcGuireSOFlemingMFSortwellCEExogenous erythropoietin provides neuroprotection of grafted dopamine neurons in a rodent model of Parkinson's diseaseBrain Res20061068221229[PubMed][Google Scholar]
157. GilJMLeistMPopovicNBrundinPPetersenAAsialoerythropoietin is not effective in the R6/2 line of Huntington's disease miceBMC Neurosci2004517[PubMed][Google Scholar]
158. AssarafMIDiazZLibermanAMillerWHJrArvanitakisZLiYBennettDASchipperHMBrain erythropoietin receptor expression in Alzheimer disease and mild cognitive impairmentJ Neuropathol Exp Neurol200766389398[PubMed][Google Scholar]
159. SpringborgJBSonneBFrederiksenHJFoldagerNPoulsgaardLKlausenTJorgensenOSOlsenNVErythropoietin in the cerebrospinal fluid of patients with aneurysmal subarachnoid haemorrhage originates from the brainBrain Res2003984143148[PubMed][Google Scholar]
160. KoehnePHochhausFFelderhoff-MueserURing-MrozikEObladenMBuhrerCVascular endothelial growth factor and erythropoietin concentrations in cerebrospinal fluid of children with hydrocephalusChilds Nerv Syst200218137141[PubMed][Google Scholar]
161. HassanKGrossBSimriWRubinchikICohenHJacobiJShashaSMKristalBThe presence of erythropoietin receptors in the human peripheral nervous systemClin Nephrol200461127129[PubMed][Google Scholar]
162. ScarlatoMPrevitaliSCCarpoMPareysonDBrianiCDel BoRNobile-OrazioEQuattriniAComiGPPolyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesisBrain200512819111920[PubMed][Google Scholar]
163. BrettschneiderJWidlKEhrenreichHRiepeMTumaniHErythropoietin in the cerebrospinal fluid in neurodegenerative diseasesNeurosci Lett2006404347351[PubMed][Google Scholar]
164. WidlKBrettschneiderJSchattauerDSussmuthSHuberRLudolphACTumaniHErythropoietin in cerebrospinal fluid: age-related reference values and relevance in neurological diseaseNeurochem Res20073211631168[PubMed][Google Scholar]
165. CariouAClaessensYEPeneFMarxJSSpauldingCHababouCCasadevallNMiraJPCarliPHermineOEarly high-dose erythropoietin therapy and hypothermia after out-of-hospital cardiac arrest: a matched control studyResuscitation200876397404[PubMed][Google Scholar]
166. HassanKSimriWRubenchikIManelisJGrossBShashaSMKristalBEffect of erythropoietin therapy on polyneuropathy in predialytic patientsJ Nephrol200316121125[PubMed][Google Scholar]
167. EhrenreichHHinze-SelchDStawickiSAustCKnolle-VeentjerSWilmsSHeinzGErdagSJahnHDegnerDRitzenMMohrAWagnerMSchneiderUBohnMHuberMCzernikAPollmacherTMaierWSirénALKlosterkotterJFalkaiPRutherEAldenhoffJBKrampeHImprovement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietinMol Psychiatry200712206220[PubMed][Google Scholar]
168. SpringborgJBMollerCGideonPJorgensenOSJuhlerMOlsenNVErythropoietin in patients with aneurysmal subarachnoid haemorrhage: a double blind randomised clinical trialActa Neurochir (Wien)200714910891101discussion 1101[PubMed][Google Scholar]